Bruker Co. (NASDAQ:BRKR) Stock Holdings Lifted by Texas Permanent School Fund Corp

Texas Permanent School Fund Corp raised its stake in Bruker Co. (NASDAQ:BRKR) by 1.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 81,161 shares of the medical research company’s stock after buying an additional 1,050 shares during the period. Texas Permanent School Fund Corp owned approximately 0.06% of Bruker worth $7,624,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Rise Advisors LLC purchased a new position in Bruker during the 1st quarter worth approximately $27,000. Lindbrook Capital LLC grew its position in Bruker by 68.2% during the 4th quarter. Lindbrook Capital LLC now owns 360 shares of the medical research company’s stock worth $26,000 after purchasing an additional 146 shares in the last quarter. Neo Ivy Capital Management purchased a new position in Bruker during the 4th quarter worth approximately $30,000. GAMMA Investing LLC purchased a new position in Bruker during the 4th quarter worth approximately $33,000. Finally, VisionPoint Advisory Group LLC grew its position in Bruker by 145.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 512 shares of the medical research company’s stock worth $32,000 after purchasing an additional 303 shares in the last quarter. Institutional investors own 79.52% of the company’s stock.

Bruker Price Performance

NASDAQ BRKR traded up $2.47 on Thursday, reaching $63.72. The company’s stock had a trading volume of 609,539 shares, compared to its average volume of 996,008. The firm has a market cap of $9.26 billion, a PE ratio of 23.17, a price-to-earnings-growth ratio of 2.10 and a beta of 1.20. The business has a 50-day moving average price of $68.43 and a 200 day moving average price of $76.67. Bruker Co. has a 52 week low of $53.79 and a 52 week high of $94.86. The company has a current ratio of 1.81, a quick ratio of 0.91 and a debt-to-equity ratio of 0.95.

Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, May 2nd. The medical research company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.07. The business had revenue of $721.70 million for the quarter, compared to analysts’ expectations of $729.88 million. Bruker had a net margin of 13.38% and a return on equity of 27.31%. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.64 earnings per share. Sell-side analysts expect that Bruker Co. will post 2.66 EPS for the current year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 17th. Shareholders of record on Monday, June 3rd were paid a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, June 3rd. This represents a $0.20 annualized dividend and a yield of 0.31%. Bruker’s dividend payout ratio is 7.27%.

Analysts Set New Price Targets

BRKR has been the topic of several research analyst reports. Citigroup lowered their price target on shares of Bruker from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Wednesday. Bank of America lowered their price target on shares of Bruker from $95.00 to $90.00 and set a “buy” rating on the stock in a report on Monday, May 20th. StockNews.com cut shares of Bruker from a “buy” rating to a “hold” rating in a report on Tuesday, May 21st. The Goldman Sachs Group lowered their price target on shares of Bruker from $72.00 to $60.00 and set a “sell” rating on the stock in a report on Tuesday. Finally, Stifel Nicolaus decreased their price objective on shares of Bruker from $81.00 to $77.00 and set a “hold” rating for the company in a report on Monday, May 20th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $81.78.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.